Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study

The characteristics of patients with RRMM in the real-world setting often differ from those enrolled in clinical trials, challenging therapeutic decisions in day-to-day practice. We retrospectively analyzed the sociodemographic and clinical characteristics of RRMM patients treated in routine clinica...

Descripción completa

Detalles Bibliográficos
Autores: Ocio, Enrique M., Montes Gaisán, Carmen, Bustamante, Gabriela, Garzón, Sebastián, González, Esther, Pérez, Ernesto, Sirvent, Maialen, Arguiñano, José María, González, Yolanda, Ríos, Rafael, Miguel, Dunia de, Grande, Marta, Fernández, Alonso, Naves, Andrea, Rosiñol Dachs, Laura
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/186100
Acceso en línea:https://hdl.handle.net/2445/186100
Access Level:acceso abierto
Palabra clave:Mieloma múltiple
Condicions econòmiques
Multiple myeloma
Economic conditions
id ES_7ea07673d3bd68df315843908dc1e448
oai_identifier_str oai:recercat.cat:2445/186100
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa StudyOcio, Enrique M.Montes Gaisán, CarmenBustamante, GabrielaGarzón, SebastiánGonzález, EstherPérez, ErnestoSirvent, MaialenArguiñano, José MaríaGonzález, YolandaRíos, RafaelMiguel, Dunia deGrande, MartaFernández, AlonsoNaves, AndreaRosiñol Dachs, LauraMieloma múltipleCondicions econòmiquesMultiple myelomaEconomic conditionsThe characteristics of patients with RRMM in the real-world setting often differ from those enrolled in clinical trials, challenging therapeutic decisions in day-to-day practice. We retrospectively analyzed the sociodemographic and clinical characteristics of RRMM patients treated in routine clinical practice and their influence on the prescribing patterns in this setting. Treatment patterns among 276 RRMM patients from multiple hospitals were highly heterogeneous. The prescribed regimen was primarily influenced by the number of previous lines and the presence of osteopenia and extramedullary plasmacytomas. Our results rise awareness on the heterogeneity of the therapeutic landscape of RRMM in the real-world and highlight the complexity of therapeutic decision making in this population. Introduction: Treatment of relapsed and/or refractory multiple myeloma (RRMM) should be established based on multiple factors, including previous treatment and the sociodemographic/clinical characteristics of the patients. However, patients enrolled in randomized-controlled trials often do not mirror the scenario encountered in real-world practice, thus challenging therapeutic decisions in day-to-day practice. Patients and methods: This observational, cross-sectional, multicenter study aimed to investigate the sociodemographic and clinical characteristics of patients with RRMM treated in routine practice in Spain and their influence on treatment regimens. Results: The study included 276 RRMM patients (median age 69 years; no gender predominance). Seventy-four percent of patients had CRAB features at the time of study inclusion, 65.9% bone lesions, 28.7% high-risk cytogenetics, and 27.0% were at ISS stage III; 65.1% were retired and lived in urban areas (75.7%) with their relatives (85.8%); 28.7% had some dependence degree. Patients had experienced their last relapse in a median of 1.61 months before enrollment and had received a median of 2 treatment lines (range 1-10). Second-and third-line therapies were mostly based on immunomodulatory drugs, followed by proteasome inhibitors (PIs), whereas monoclonal antibodies prevailed in later treatment lines. The presence of extramedullary plasmacytomas, the absence of osteopenia, and being in the second or third treatment line (vs. later lines) significantly increased the odds of receiving PIs. Conclusions: RRMM treatment in the real-world setting is highly heterogeneous and is pr imar ily influenced by the number of previous lines. The consideration of patients' clinical and sociodemographic characteristics may support clinicians in making therapeutic decisions.Elsevier2022202220212022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9 p.application/pdfhttps://hdl.handle.net/2445/186100Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1016/j.clml.2021.10.001Clinical Lymphoma Myeloma and Leukemia, 2021, vol. 22, num. 4, p. e241-e249https://doi.org/10.1016/j.clml.2021.10.001cc by (c) Ocio, Enrique M. et al, 2022http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1861002026-05-29T05:05:01Z
dc.title.none.fl_str_mv Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
title Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
spellingShingle Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
Ocio, Enrique M.
Mieloma múltiple
Condicions econòmiques
Multiple myeloma
Economic conditions
title_short Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
title_full Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
title_fullStr Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
title_full_unstemmed Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
title_sort Clinical and Sociodemographic Characteristics of Patients with Relapsed and/or Refractory Multiple Myeloma and their influence on Treatment in the Real-World Setting in Spain: the CharisMMa Study
dc.creator.none.fl_str_mv Ocio, Enrique M.
Montes Gaisán, Carmen
Bustamante, Gabriela
Garzón, Sebastián
González, Esther
Pérez, Ernesto
Sirvent, Maialen
Arguiñano, José María
González, Yolanda
Ríos, Rafael
Miguel, Dunia de
Grande, Marta
Fernández, Alonso
Naves, Andrea
Rosiñol Dachs, Laura
author Ocio, Enrique M.
author_facet Ocio, Enrique M.
Montes Gaisán, Carmen
Bustamante, Gabriela
Garzón, Sebastián
González, Esther
Pérez, Ernesto
Sirvent, Maialen
Arguiñano, José María
González, Yolanda
Ríos, Rafael
Miguel, Dunia de
Grande, Marta
Fernández, Alonso
Naves, Andrea
Rosiñol Dachs, Laura
author_role author
author2 Montes Gaisán, Carmen
Bustamante, Gabriela
Garzón, Sebastián
González, Esther
Pérez, Ernesto
Sirvent, Maialen
Arguiñano, José María
González, Yolanda
Ríos, Rafael
Miguel, Dunia de
Grande, Marta
Fernández, Alonso
Naves, Andrea
Rosiñol Dachs, Laura
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Mieloma múltiple
Condicions econòmiques
Multiple myeloma
Economic conditions
topic Mieloma múltiple
Condicions econòmiques
Multiple myeloma
Economic conditions
description The characteristics of patients with RRMM in the real-world setting often differ from those enrolled in clinical trials, challenging therapeutic decisions in day-to-day practice. We retrospectively analyzed the sociodemographic and clinical characteristics of RRMM patients treated in routine clinical practice and their influence on the prescribing patterns in this setting. Treatment patterns among 276 RRMM patients from multiple hospitals were highly heterogeneous. The prescribed regimen was primarily influenced by the number of previous lines and the presence of osteopenia and extramedullary plasmacytomas. Our results rise awareness on the heterogeneity of the therapeutic landscape of RRMM in the real-world and highlight the complexity of therapeutic decision making in this population. Introduction: Treatment of relapsed and/or refractory multiple myeloma (RRMM) should be established based on multiple factors, including previous treatment and the sociodemographic/clinical characteristics of the patients. However, patients enrolled in randomized-controlled trials often do not mirror the scenario encountered in real-world practice, thus challenging therapeutic decisions in day-to-day practice. Patients and methods: This observational, cross-sectional, multicenter study aimed to investigate the sociodemographic and clinical characteristics of patients with RRMM treated in routine practice in Spain and their influence on treatment regimens. Results: The study included 276 RRMM patients (median age 69 years; no gender predominance). Seventy-four percent of patients had CRAB features at the time of study inclusion, 65.9% bone lesions, 28.7% high-risk cytogenetics, and 27.0% were at ISS stage III; 65.1% were retired and lived in urban areas (75.7%) with their relatives (85.8%); 28.7% had some dependence degree. Patients had experienced their last relapse in a median of 1.61 months before enrollment and had received a median of 2 treatment lines (range 1-10). Second-and third-line therapies were mostly based on immunomodulatory drugs, followed by proteasome inhibitors (PIs), whereas monoclonal antibodies prevailed in later treatment lines. The presence of extramedullary plasmacytomas, the absence of osteopenia, and being in the second or third treatment line (vs. later lines) significantly increased the odds of receiving PIs. Conclusions: RRMM treatment in the real-world setting is highly heterogeneous and is pr imar ily influenced by the number of previous lines. The consideration of patients' clinical and sociodemographic characteristics may support clinicians in making therapeutic decisions.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/186100
url https://hdl.handle.net/2445/186100
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.clml.2021.10.001
Clinical Lymphoma Myeloma and Leukemia, 2021, vol. 22, num. 4, p. e241-e249
https://doi.org/10.1016/j.clml.2021.10.001
dc.rights.none.fl_str_mv cc by (c) Ocio, Enrique M. et al, 2022
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Ocio, Enrique M. et al, 2022
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411749268029440
score 15,811543

Similares en LA Referencia